Keap1-Nrf2

Nrf2-IN-1 (Compound 4f) is an inhibitor of nuclear factor-erythroid 2-related factor 2 (Nrf2), acts as a promising agent in acute myeloid leukemia (AML) therapy.

Oltipraz inhibits HIF-1alpha activity and HIF-1alpha-dependent tumor growth, which may result from a decrease in HIF-1alpha stability through S6K1 inhibition in combination with an H2O2-scavenging effect.

RTA-408 is a synthetic triterpenoid that potently activates the antioxidative transcription factor Nrf2 and inhibits the proinflammatory transcription factor NF-kB.

CDDO-EA is an activator of Nrf2/ARE; Neuroprotective effect.

NK-252 is a Nrf2 activator, exhibits a greater Nrf2-activating potential than OPZ.

Brusatol is a biochemical, isolated from the Brucea javanica plant, that inhibits Nrf2.

ML-385 is an inhibitor of nuclear factor erythroid 2-related factor 2 (Nrf2) with IC50 value of 1.9 μM.

AKBA (Acetyl-11-keto-β-boswellic acid) is an active triterpenoid compound from the extract of Boswellia serrate and a novel Nrf2 activator.

(R)-Sulforaphane is a highly potent inducer of the Keap1/Nrf2/ARE pathway. (R)-Sulforaphane is a far more potent inducer of the carcinogen-detoxifying enzyme systems in rat liver and lung than the S-isomer.